A Single-dose, Open-label, Randomized, Crossover Study to Assess the Relative Bioavailability of the Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Administered Orally as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Cobicistat/darunavir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 06 Mar 2017 Status changed from recruiting to completed.
- 20 Jan 2017 Status changed from not yet recruiting to recruiting.
- 12 Dec 2016 New trial record